✦ LIBER ✦

Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma

✍ Scribed by Susan C. Baer; Delray Schultz; Marie Synnestvedt; David E. Elder

Book ID: 102675612
Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 555 KB
Volume: 76
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19951201)76:11<2242::aid-cncr2820761110>3.0.co;2-i

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic variables for patients with s

Prognostic variables for patients with stage III malignant melanoma

✍ G. E. Messaris; M. M. Konstadoulakis; N. Ricaniadis; E. Leandros; G. Androulakis 📂 Article 📅 2000 🏛 Taylor and Francis Group ⚖ 49 KB

Prognostic implications of DNA index in

Prognostic implications of DNA index in patients with stage III cutaneous melanoma

✍ Keith M. Heaton; Mary B. Rippon; Adel El-Naggar; Susan L. Tucker; Merrick I. Ros 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 596 KB

Malignant melanoma patients with positiv

Malignant melanoma patients with positive nodes and relatively good prognoses: Microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes

✍ Calvin L. Day Jr; Dr. Arthur J. Sober; Robert A. Lew; Martin C. Mihm Jr.; Thomas 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 718 KB

Acral with melanoma: A review of 185 pat

Acral with melanoma: A review of 185 patients identification of prognostic variables

✍ Craig L. Slingluff Jr.; Robin Vollmer; Hilliard F. Seigler 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 777 KB

Cutaneous malignant melanoma (arizona ca

Cutaneous malignant melanoma (arizona cancer center experience). I. Natural history and prognostic factors influencing survival in patients with stage i disease

✍ Frank L. Meyskens Jr; Donald H. Berdeaux; Bruce Parks; Tony Tong; Lois Loescher; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 719 KB

The authors have studied the natural history of 377 patients with Stage I cutaneous malignant melanoma followed at the Arizona Cancer Center, Tucson. Two hundred eight patients, or 55%, remained free of metastatic disease after a median follow-up of 30 months. The survival at 5,8, and 10 years was 6

In Reply: Cost Effectiveness of Staging

In Reply: Cost Effectiveness of Staging Procedures in Patients with Stage I/II Melanoma

✍ Rachael L. Morton; Kirsten Howard; John F. Thompson 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 139 KB